SBP-7455 是一种高亲和力，可口服的双重ULK1/ULK2自噬抑制剂，可有效抑制ULK1/2酶活性，可研究三阴性乳腺癌，在 ADP-Glo 分析中的IC50分别为 13 nM 和 476 nM。

SBP-7455 potently inhibited ULK1/2 enzymatic activity in vitro and in cells, reduced the viability of TNBC cells and had oral bioavailability in mice.

SBP-7455 treatment inhibits cell growth with an IC50 of 0.3 μM for MDA-MB-468 cells. SBP-7455 inhibits starvation-induced autophagic flux in TNBC cells that are dependent on autophagy for survival[1].

To evaluate the PD profile and in vivo target engagement, mice were dosed with SBP-7455 (10 mg/kg) or vehicle by oral gavage, and liver samples were collected after 2 h.Based on the PK and PD profiles, our data show that SBP-7455 is an efficacious tool that can be used to modulate autophagy in vivop[1].

1884222-74-5

C16H17F3N4O2

354.333

DMSO:120mg/mL (338.67 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years